Viking Therapeutics/VKTX
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About Viking Therapeutics
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Ticker
VKTX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
San Diego, United States
Employees
28
Website
www.vikingtherapeutics.com
VKTX Metrics
BasicAdvanced
$5.7B
Market cap
-
P/E ratio
-$0.93
EPS
1.10
Beta
-
Dividend rate
Price and volume
Market cap
$5.7B
Beta
1.1
Financial strength
Current ratio
29.485
Quick ratio
29.382
Long term debt to equity
0.091
Total debt to equity
0.126
Interest coverage (TTM)
-1,299.58%
Management effectiveness
Return on assets (TTM)
-12.78%
Return on equity (TTM)
-17.55%
Valuation
Price to book
6.1
Price to tangible book (TTM)
6.1
Price to free cash flow (TTM)
-94.52
Growth
Earnings per share change (TTM)
-0.71%
3-year earnings per share growth
15.88%
What the Analysts think about VKTX
Analyst Ratings
Majority rating from 11 analysts.
VKTX Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$27M
10.98%
Profit margin
0.00%
NaN%
VKTX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.19
-$0.23
-$0.25
-$0.26
-
Expected
-$0.19
-$0.22
-$0.25
-$0.28
-$0.27
Surprise
-1.23%
4.98%
-1.32%
-6.47%
-
VKTX News
AllArticlesVideos
Viking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association
PRNewsWire·1 week ago
Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
PRNewsWire·4 weeks ago
Viking Therapeutics to Participate at Upcoming Investor Conferences
PRNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Viking Therapeutics stock?
Viking Therapeutics (VKTX) has a market cap of $5.7B as of July 04, 2024.
What is the P/E ratio for Viking Therapeutics stock?
The price to earnings (P/E) ratio for Viking Therapeutics (VKTX) stock is 0 as of July 04, 2024.
Does Viking Therapeutics stock pay dividends?
No, Viking Therapeutics (VKTX) stock does not pay dividends to its shareholders as of July 04, 2024.
When is the next Viking Therapeutics dividend payment date?
Viking Therapeutics (VKTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Viking Therapeutics?
Viking Therapeutics (VKTX) has a beta rating of 1.1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Viking Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.